Factor VIIa-CTP

Drug Profile

Factor VIIa-CTP

Alternative Names: FVII-CTP; MOD-5014; MOD-5017

Latest Information Update: 15 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PROLOR Biotech
  • Developer OPKO Health
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants
  • Mechanism of Action Factor VIIa stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia
  • New Molecular Entity No

Highest Development Phases

  • Phase II Haemophilia

Most Recent Events

  • 21 Feb 2018 Opko Biologics completes a phase I trial in Haemophilia (In volunteers) in Israel (SC) (NCT02919800)
  • 27 Sep 2016 Opko plans a phase I trial in Healthy male volunteers in USA (NCT02919800)
  • 04 Mar 2016 9192079 - checked against MR, no relevant updates
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top